New microcatheter achieves 100% success in first cases.
Vantis Vascular announced the first commercial use of its CrossFast integrated microcatheter delivery system in 10 complex high-risk coronary interventions (CHiP). Performed at St. John’s Hospital in Detroit by Dr. Amir Kaki, the cases achieved 100% procedural success, demonstrating exceptional deliverability in challenging anatomies with no device-related complications.
Key Highlights
- Breakthrough Design: Dual monorail with DuoPro interlocking technology ensures unmatched pushability and precise stent delivery.
- Clinical Performance: Delivered stents where traditional guide catheters failed, navigating tight, highly calcified vessels with ease.
Dr. Kaki remarked:
“CrossFast simplifies coronary interventions, reducing complexity and enhancing patient outcomes.”
FDA Cleared and U.S. Rollout Underway
- FDA Clearance: October 2024.
- Availability: Limited release in the U.S.; full launch expected later this year.
Vantis plans to build on CrossFast’s success with its CrossShock intravascular lithotripsy system under development.
Future Outlook
Dr. Frank Saltiel, Chief Clinical Officer at Vantis, stated:
“CrossFast redefines coronary therapy, minimising complications and procedure times in the most complex cases.”
